BlossomHill Therapeutics, Inc. Common Stock (BLSM) - Net Assets
Based on the latest financial reports, BlossomHill Therapeutics, Inc. Common Stock (BLSM) has net assets worth $-152.12 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($143.41 Million) and total liabilities ($295.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See BLSM net asset quality score to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-152.12 Million |
| % of Total Assets | -106.07% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BlossomHill Therapeutics, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how BlossomHill Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see BLSM stock market capitalisation.
Annual Net Assets for BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025. Also explore BlossomHill Therapeutics, Inc. Common St equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-131.73 Million | -80.74% |
| 2024-12-31 | $-72.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BlossomHill Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6055500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Components | $3.30 Million | % |
| Total Equity | $-131.73 Million | 100.00% |
BlossomHill Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of BlossomHill Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhongbai Holdings Group Co Ltd
SHE:000759
|
$639.80 Million |
|
Shenandoah Telecommunications Co
NASDAQ:SHEN
|
$640.08 Million |
|
Neurogene Inc
NASDAQ:NGNE
|
$640.21 Million |
|
PNE AG
XETRA:PNE3
|
$640.34 Million |
|
Achieve Life Sciences Inc
NASDAQ:ACHV
|
$639.57 Million |
|
Sumber Global Energy Tbk Pt
JK:SGER
|
$639.33 Million |
|
Stx Engine
KO:077970
|
$639.23 Million |
|
Slate Grocery REIT
TO:SGR-UN
|
$639.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BlossomHill Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -72,883,000 to -131,728,000, a change of -58,845,000.
- Net loss of 60,555,000 reduced equity.
- New share issuances of 83,938,000 increased equity.
- Other factors decreased equity by 82,228,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-60.55 Million | -45.97% |
| Share Issuances | $83.94 Million | +63.72% |
| Other Changes | $-82.23 Million | -62.42% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BlossomHill Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-2.51 | $25.74 | x |
| 2025-12-31 | $-4.53 | $25.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BlossomHill Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.41 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-47.38 Million |
Industry Comparison
This section compares BlossomHill Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $86,936,133
- Average return on equity (ROE) among peers: -19.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. Common Stock (BLSM) | $-152.12 Million | 0.00% | N/A | $639.79 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $117.14 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $318.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $992.51 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.17 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $431.75 Million | -14.19% | 0.73x | $4.70 Billion |
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients w… Read more